Avelumab治疗既往经治的转移性或复发性非小细胞肺癌(JAVELIN Solid Tumor):一项多中心、开放标签、1b期试验的剂量扩展队列
该剂量扩展队列纳入184例含铂方案治疗后进展或耐药的转移性或复发性非小细胞肺癌患者,接受avelumab 10 mg/kg每2周静脉给药。确认客观缓解率为12%(95%CI 8-18),疾病控制率50%,治疗相关3级及以上不良事件发生率为13%。
要点
- avelumab在经铂治疗的进展或耐药非小细胞肺癌中确认客观缓解率为12%(95%CI 8-18)。
- 184例中92例(50%)达到疾病控制,22例(12%)出现免疫相关治疗相关事件。
- 治疗相关3级及以上不良事件发生于23例(13%),严重治疗相关不良事件16例(9%)。
核心结论
- avelumab在进展性或治疗耐药的非小细胞肺癌患者中显示可接受的安全性特征和抗肿瘤活性,为在该疾病背景下进一步研究avelumab提供了依据。
研究设计与样本
- 本研究为多中心、开放标签、1期试验的剂量扩展队列,在美国58个癌症治疗中心和学术医院入组患者。
- 2013年9月10日至2014年6月24日期间入组184例并开始avelumab治疗,中位随访8.8个月(IQR 7.2-11.9)。
- 入组患者为经铂治疗的进展性或铂耐药转移性或复发性非小细胞肺癌,分期为IIIB或IV期,含鳞癌或非鳞癌组织学。
- 患者选择不基于PD-L1表达或其他生物标志物(包括EGFR或KRAS突变或ALK易位状态)。
- 患者接受avelumab单药10 mg/kg每2周静脉输注直至疾病进展或毒性,主要目标为评估安全性和耐受性。
主要发现
- 任何级别最常见的治疗相关不良事件为疲乏(46/184,25%)、输注相关反应(38/184,21%)和恶心(23/184,13%)。
- 184例中23例(13%)发生3级及以上治疗相关不良事件,最常见(超过2例)为输注相关反应(4例,2%)和脂肪酶升高(3例,2%)。
- 184例中16例(9%)发生与avelumab治疗相关的严重不良事件,输注相关反应(4例,2%)和呼吸困难(2例,1%)发生于超过1例患者。
- 184例中22例(12%[95%CI 8-18])达到确认客观缓解,包括1例完全缓解和21例部分缓解;70例(38%)疾病稳定;92例(50%)达到疾病控制。
- 184例中80例(44%)发生任何原因的严重不良事件,超过5例(≥3%)的为呼吸困难(10例,5%)、肺炎(9例,5%)和慢性阻塞性肺疾病(6例,3%);22例(12%)发生免疫相关治疗相关事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in patients with advanced solid tumours in a dose-escalation phase 1a trial. In this dose-expansion cohort of that trial, we assess avelumab treatment in a cohort of patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC). METHODS: In this dose-expansion cohort of a multicentre, open-label, phase 1 study, patients with progressive or platinum-resistant metastatic or recurrent NSCLC were enrolled at 58 cancer treatment centres and academic hospitals in the USA. Eligible patients had confirmed stage IIIB or IV NSCLC with squamous or non-squamous histology, measurable disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), tumour biopsy or archival sample for biomarker assessment, and Eastern Cooperative Oncology Group performance status 0 or 1, among other criteria. Patient selection was not based on PD-L1 expression or expression of other biomarkers, including EGFR or KRAS mutation or ALK translocation status. Patients received infusional avelumab monotherapy 10 mg/kg every 2 weeks until disease progression or toxicity. The primary objective was to assess safety and tolerability. This trial is registered with ClinicalTrials.gov, number NCT01772004; enrolment in this cohort is closed and the trial is ongoing. FINDINGS: Between Sept 10, 2013, and June 24, 2014, 184 patients were enrolled and initiated treatment with avelumab. Median follow-up duration was 8·8 months (IQR 7·2-11·9). The most common treatment-related adverse events of any grade were fatigue (46 [25%] of 184 patients), infusion-related reaction (38 [21%]), and nausea (23 [13%]). Grade 3 or worse treatment-related adverse events occurred in 23 (13%) of 184 patients; the most common (occurring in more than two patients) were infusion-related reaction (four [2%] patients) and increased lipase level (three [2%]). 16 (9%) of 184 patients had a serious adverse event related to treatment with avelumab, with infusion-related reaction (in four [2%] patients) and dyspnoea (in two [1%]) occurring in more than one patient. Serious adverse events irrespective of cause occurred in 80 (44%) of 184 patients. Those occurring in more than five patients (≥3%) were dyspnoea (ten patients [5%]), pneumonia (nine [5%]), and chronic obstructive pulmonary disease (six [3%]). Immune-related treatment-related events occurred in 22 patients (12%). Of 184 patients, 22 (12% [95% CI 8-18]) achieved a confirmed objective response, including one complete response and 21 partial responses. 70 (38%) had stable disease. Overall, 92 (50%) of 184 patients achieved disease control (they had a confirmed response or stable disease as their best overall response). One patient was initially thought to have died from grade 5 radiation pneumonitis during the study; however, this adverse event was subsequently regraded to grade 3 and the death was attributed to disease progression. INTERPRETATION: Avelumab showed an acceptable safety profile and antitumour activity in patients with progressive or treatment-resistant NSCLC, providing a rationale for further studies of avelumab in this disease setting. FUNDING: Merck KGaA and Pfizer.
引用
- Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017. PMID: 28373005. doi:10.1016/S1470-2045(17)30240-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。